What is coming up next?
Primary endpoint: OS
JAVELIN bladder 100 (NCT02603432)
MANTEINANCE STUDY
BSC
Avelumab + BSC
•
≥1 prior platinum-containing
regimens
N=668
R
IMvigor211 (NCT02302807)
Investigator’s choice
(vinflunine, paclitaxel,
docetaxel)
Atezolizumab
•
2/3L platinum failure
•
ECOG PS 0–1 (PS 2 excluded)
•
Locally advanced/metastatic
N=767
R
Primary endpoint: OS
Many more strategies….
